↓ Skip to main content

Prognosis of ovarian cancer in women with type 2 diabetes using metformin and other forms of antidiabetic medication or statins: a retrospective cohort study

Overview of attention for article published in BMC Cancer, July 2018
Altmetric Badge

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
30 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Prognosis of ovarian cancer in women with type 2 diabetes using metformin and other forms of antidiabetic medication or statins: a retrospective cohort study
Published in
BMC Cancer, July 2018
DOI 10.1186/s12885-018-4676-z
Pubmed ID
Authors

Elina Urpilainen, Mikko Marttila, Ari Hautakoski, Martti Arffman, Reijo Sund, Pirjo Ilanne-Parikka, Reetta Arima, Jenni Kangaskokko, Ulla Puistola, Marianne Hinkula, Esa Läärä

Abstract

Ovarian cancer is one of the most lethal cancers and women with type 2 diabetes (T2D) have even poorer survival from it. We assessed the prognosis of ovarian cancer in women with type 2 diabetes treated with metformin, other forms of antidiabetic medication, or statins. Study cohort consisted of women with T2D diagnosed with ovarian cancer in Finland 1998-2011. They were identified from a nationwide diabetes database (FinDM), being linked to several national registers. Patients were grouped according to their medication in the three years preceding ovarian cancer diagnosis. The Aalen-Johansen estimator was used to describe cumulative mortality from ovarian cancer and from other causes in different medication groups. Mortality rates were analysed by Cox models, and adjusted hazard ratios (HR) with 95% confidence intervals (95% CIs) were estimated in relation to the use of different forms of medication. Main outcome measures were death from ovarian cancer and death from other causes. During the accrual period 421 newly diagnosed ovarian cancers were identified in the FinDM database. No evidence was found for any differences in mortality from ovarian cancer or other causes between different antidiabetic medication groups. Pre-diagnostic use of statins was observed to be associated with decreased mortality from ovarian cancer compared with no such use (HR 0.72, 95% CI 0.56-0.93). Our findings are inconclusive as regards the association between metformin and ovarian cancer survival. However, some evidence was found for improved prognosis of ovarian cancer with pre-diagnostic statin use, requiring cautious interpretation, though.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 30 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 8 27%
Student > Ph. D. Student 4 13%
Unspecified 3 10%
Student > Master 3 10%
Other 3 10%
Other 5 17%
Unknown 4 13%
Readers by discipline Count As %
Medicine and Dentistry 11 37%
Biochemistry, Genetics and Molecular Biology 6 20%
Unspecified 3 10%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Psychology 1 3%
Other 2 7%
Unknown 6 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 August 2018.
All research outputs
#10,605,829
of 13,322,622 outputs
Outputs from BMC Cancer
#3,302
of 4,987 outputs
Outputs of similar age
#200,327
of 268,290 outputs
Outputs of similar age from BMC Cancer
#1
of 1 outputs
Altmetric has tracked 13,322,622 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,987 research outputs from this source. They receive a mean Attention Score of 4.0. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 268,290 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 13th percentile – i.e., 13% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them